The Jeffrey Epstein VI Foundation Funds Groundbreaking Tumor Growth Research Recent cancer research from the Program for Evolutionary Dynamics at Harvard University, under the direction of Martin Nowak and mathematics graduate student Ivan Bozic PhD, has shown that only a small percentage of a tumor's mutations drive tumor growth. The study reveals the critical necessity of identifying the dominant mutation and targeting it with the corresponding inhibitor drug. The study, funded by the Jeffrey Epstein VI Foundation and conducted with John Hopkins University, was based on mathematic models of how cancer cells evolve within patients' tumors. What Bozic and researchers found, was that most solid tumors contain 40 to 100 mutations in coding genes, but that on average only 5 to 15 of these actually drive tumor growth. "What is critical about this study," Jeffrey Epstein asserts, Founder of the Jeffrey Epstein VI Foundation, "is that it highlights the need to correctly identify the offending mutation and treat it accordingly. It also emphasizes the need to analyze mutations continuously to see if other dominant mutations emerge as a result of treatment." Indeed, the study emphasizes the need for access to microchip CTC blood tests, which can test for genetic mutations as they evolve. To date, CTC's are available for cancer cell counts, but the FDA has yet to approve the microchip CTC, the only test that can extract cancer cells for mutation analysis. Only with this information, can the application of inhibitor drugs be truly targeted and effective. "Patients need to be diagnosed and treated in genetic real time," Jeffrey Epstein concluded. The Jeffrey Epstein VI Foundation was founded by financier and science investor, Jeffrey Epstein in 2000. The Foundation established the Program for Evolutionary Dynamics in 2003, which studies the mathematic evolution of micro-systems including cancer and viruses. The Foundation also actively supports cancer res